Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-E-Gel is a brand name for a formulation of **estradiol**, a naturally occurring estrogen used as hormone replacement therapy (HRT) in menopausal women. It is primarily indicated for the relief of moderate to severe vasomotor symptoms (hot flashes) and vulvovaginal atrophy (vaginal dryness and irritation) associated with menopause. As an agonist of the estrogen receptors alpha (ERα) and beta (ERβ), estradiol mimics the effects of endogenous hormones to stabilize physiological functions disrupted by declining estrogen levels. Clinical use requires caution in women with an intact uterus due to the risk of endometrial hyperplasia, which typically necessitates the co-administration of a progestogen. Bio-E-Gel is contraindicated in patients with a history of breast cancer, uterine cancer, or other hormone-dependent malignancies. The drug is known to interact with hepatic enzyme inducers such as carbamazepine, phenobarbital, and rifampin, which may decrease its therapeutic efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bio-E-Gel.